Trump Launches TrumpRx to Lower Drug Costs

The Trump administration unveiled TrumpRx.gov on Feb.5, a direct-to-consumer website it says will help patients buy prescription drugs at a discounted rate if they pay cash rather than through their health insurance.

“You’re going to save a fortune,” President Donald Trump said during the launch event. “And this is also so good for overall health care.”

The website launched with 43 drugs from five companies that reached agreements with the Trump administration, including AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer. According to the White House, discounts from an additional 11 companies that have reached deals with the administration will be available over the coming months.

"It's the biggest thing to happen in health care, I think, in many, many decades," President Trump added.

The government-operated platform is set up as a central hub, guiding patients to drugmakers’ direct-to-consumer sites where discounts are offered on certain products, or providing Americans with discount coupons to use at pharmacies.

In recent months, Pfizer, Lily, and at least 14 other drugmakers have negotiated deals with the administration to participate on the website and voluntarily provide certain medications at a lower cost to Medicaid patients.

President Trump and his administration announced the TrumpRx concept in the fall of 2025 as part of an agreement with pharmaceutical companies to provide lower prices for American consumers. Drugmakers agreed to lower their rates for Medicaid, administer future new drugs at prices similar to those in other wealthy nations, and offer discounts through the platform, as mentioned previously, in exchange for exemptions from certain tariffs.

“We’re tired of subsidizing the world,” Trump expressed during the event, referring to the prices of medications.

The website is the Trump administration’s latest attempt to tackle U.S prescription drug pricing, which, according to the Rand Corp., a public policy think tank, is on average two to three times higher than in other developed countries and up to 10 times higher than in some others.